AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer.

AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal

Merck

Merck and AstraZeneca both appear to be well-positioned for the future. Both boast above-average dividends that look to remain viable.

Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years

AstraZeneca said on Friday a combination of its cancer drugs Imfinzi and Lynparza when added to platinum-based chemotherapy showed positive results in a late-stage trial in patients with advanced or recurrent endometrial cancer.

AstraZeneca's drug combo shows positive results in late-stage cancer trial

AstraZeneca PLC (LSE:AZN) has hailed the potential of a highly targeted combination of its own drugs with chemotherapy in the battle against endometrial cancer. This followed the read-out from the DUO-E phase III trial, which demonstrated impressive outcomes.

AstraZeneca hails the findings from cancer combination trial

AstraZeneca's price has moved sideways in the past month, after showing good progress for some time. A look at its numbers reveals that it is going strong, and will continue to do so in the foreseeable future. However, it is fairly valued at this time.

AstraZeneca: Think Medium-To-Long Term

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to revolutionize cancer care with new data across its industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to 6, 2023. More than 130 abstracts will feature 22 approved and potential new medicines across the Company's diverse oncology portfolio and pipeline, including 11 oral presentations and a late-breaking plenary presentation of overall survival (OS) resul.

AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023

WILMINGTON, Del.--(BUSINESS WIRE)--Results from the EROS real-world retrospective study showed that initiating fixed-dose triple-combination therapy BREZTRI AEROSPHERE® (budesonide/glycopyrronium/formoterol fumarate) within 30 days of a qualifying moderate or severe exacerbation in patients with COPD (chronic obstructive pulmonary disease) is associated with a decreased risk of future exacerbations by 24% vs. delaying treatment by one to six months, and by 34% vs. delaying treatment six months.

New AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPD

Pfizer

Throughout financial history, equity markets have navigated bull and bear cycles. The same holds true for various sectors.

3 Undervalued Pharma Stocks to Buy for High Total Returns

Chevron

JPMorgan Chase & Co

Rio Tinto plc Sponsored

Tesla

Walmart

Exxon Mobil

In the last decade, few companies have touched the magic trillion-dollar valuation. Apple (NASDAQ: AAPL ), Amazon (NASDAQ: AMZN ), and Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ) are the names worth mentioning.

The 7 Next Trillion-Dollar Companies to Invest in Now

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced a new license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for the technology underlying its Pin-point™ base editing system, a next-generation modular gene editing platform with a strong safety profile. Dr. Alan Fletcher, Senior Vice President, Life Sciences at Revvity, said, “Our fundamental goal for the Pin-point platform is to translate the technology from pre-clinical research into the clinic, and ultimately, i.

Revvity Announces New License Agreement for Next-Generation Base Editing Technology

The combination of AstraZeneca's cancer drug, Tagrisso, with chemotherapy to treat patients with a type of lung cancer showed positive results in a late-stage trial, the company said on Wednesday.

AstraZeneca's Tagrisso, chemo combination shows promise in lung cancer trial

We continue our analytics coverage of AstraZeneca PLC with a "hold" rating for the next 12 months. AstraZeneca's revenue for the first three months of 2023 was $10.88 billion, down 2.9% from the previous quarter and 4.5% from the first quarter of 2022.

Is AstraZeneca Overvalued After Publishing Q1 2023 Financial Results?

AstraZeneca delivered solid results to its shareholders in the first quarter. The British drugmaker spends nearly a quarter of its revenue on R&D.

Is AstraZeneca Stock a Buy for Growth Investors?

Johnson & Johnson

Microsoft

Novartis

VanEck Vectors Pharmaceutical ETF

Industry-leading pharmaceutical firms are adopting artificial intelligence to drive value for the future of their enterprise. Several companies in the VanEck Pharmaceutical ETF are currently integrating AI into their operations.

How The Pharmaceutical Industry Is Using AI

SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Cullgen Raises $40 Million in New Financing Led by AstraZeneca-CICC Fund.

Cullgen Raises $40 Million in New Financing Led by AstraZeneca-CICC Fund

Newmont Mining

With another rate hike by the Fed, the markets remain in an uncertain zone. In all probability, the Fed will pause on rate hikes.

3 Low-Volatility Stocks for a Stable Investment Strategy

AstraZeneca PLC (LSE:AZN) forecasts for its major Lynparza drug are expected to be trimmed following an advisory vote against full approval in the US.  In a US Food & Drug Administration advisory committee meeting to discuss Lynparza's regulatory filling for first-line metastatic castrate-resistant prostate cancer (mCRPC), based on Phase III data, the committee voted 11-1 against approving the drug in an all-comer population.

AstraZeneca FDA vote worth potentially US$500mln annual peak sales

AstraZeneca PLC (LSE:AZN) has suffered a setback in its bid to deploy a key drug broadly in prostate cancer, with an influential US panel calling for a limit on its use. The Oncologic Drugs Advisory Committee (ODAC) told the Food and Drug Administration (FDA) that Lynparza, when combined with other drugs, showed a favourable benefit-risk profile for certain patients with advanced prostate cancer.

AstraZeneca disappointed by US panel recommendation for prostate cancer drug

AstraZeneca PLC (AZN) Q1 2023 Earnings Call Transcript.

AstraZeneca PLC (AZN) Q1 2023 Earnings Call Transcript

AstraZeneca (AZN) beats first-quarter estimates for earnings while missing the same for sales. The company reaffirms its 2023 guidance.

AstraZeneca (AZN) Q1 Earnings Beat, COVID Products Hurt Sales

Just over £4bn was added to the value of AstraZeneca PLC, whose shares opened 2.25% higher after the company reported better-than-expected first-quarter profit and revenue. Adjusted earnings of $1.92 per share on sales of approximately $10.9 billion, outpaced the average analyst estimate of $1.71 per share on sales of around $10.6 billion.

AstraZeneca's Q1 beat adds £4bn to the value of the drug giant

Flowers Foods

McDonald's

PepsiCo

Mondelez

Visa

If you're looking for some low-risk stocks for inflation-proofing, investing in historically stable companies with robust cash flows and dividends is the best bet right now. A recession is on the cards later this year, and if you are only worried about protecting what you have while having returns that can beat inflation, I would not recommend investing in many of the hotter growth stocks this year.

7 Low-Risk Stocks to Buy if You Only Want to Beat Inflation

AstraZeneca delivers its first-quarter results Thursday on a hot streak. Shares have risen 15% in a month consolidating its position as the UK's largest company and no doubt pleasingly for boss Pascal Soriot overtaking one-time bidder Pfizer in the process Astra's resurgence has been impressive with the growth drivers its trio of blockbuster therapiesTagrisso, Lynparza and Imfinzi.

AstraZeneca in uncharted waters as shares rocket higher

GlaxoSmithKline

GSK's first quarter should see the UK pharma in decent shape operationally says analysts though the ongoing legal battle over Zantac compensation will remain the main influence on the share price until resolved. What investors would like is some of the pipeline-driven growth long-term rival AstraZeneca has produced over the last few years.

GSK minds the gap as AstraZeneca streaks ahead

When the opening bell rings on Thursday, a quintet of Big Pharma players will have just reported earnings, giving investors a picture of how the sector fared to start 2023.  Eli Lily and Company, Merck & Co, AstraZeneca PLC (LSE:AZN), Sanofi and Bristol-Myers Squibb are all expected to release their financials.

Big Pharma earnings bonanza could shape sector going forward: PREVIEW

News for AstraZeneca Stock (AZN)